Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Am J Clin Nutr ; 118(2): 382-390, 2023 08.
Article in English | MEDLINE | ID: mdl-37269909

ABSTRACT

BACKGROUND: Preclinical studies suggest that blueberry consumption is associated with improved bone health. OBJECTIVES: We conducted a blueberry dose-response study in ovariectomized (OVX)-rats that informed a study in postmenopausal women using the urinary appearance of calcium (Ca) tracers from prelabeled bone to reflect changes in bone balance. We hypothesized that blueberry consumption would reduce bone loss in a dose-dependent manner compared with no treatment. METHODS: OVX rats were fed 4 doses of blueberry powder (2.5%, 5%, 10%, and 15%) in randomized order to determine bone 45Ca retention. Fourteen healthy, nonosteoporotic women ≥4 y past menopause were dosed with 50 nCi of 41Ca, a long-lived radioisotope, and equilibrated for 5 mo to allow 41Ca deposition in bone. Following a 6-wk baseline period, participants were assigned to a random sequence of 3 6-wk interventions, a low (17.5 g/d), medium (35 g/d), or high (70 g/d) dose of freeze-dried blueberry powder equivalent to 0.75, 1.5, or 3 cups of fresh blueberries incorporated into food and beverage products. Urinary 41Ca:Ca ratio was measured by accelerator mass spectrometry. Serum bone resorption biomarkers and urinary polyphenols were measured at the end of each control and intervention period. Data were analyzed using a linear mixed model and repeated measures analysis of variance. RESULTS: In both OVX rats and postmenopausal women, blueberry interventions benefited net bone calcium balance at lower but not at higher doses. In women, net bone calcium retention increased by 6% with the low (95% CI: 2.50, 8.60; P < 0.01) and 4% with the medium (95% CI: 0.96, 7.90; P < 0.05) dose compared with no treatment. Urinary excretion of hippuric acid increased dose-dependently with blueberry consumption. No significant relationships were found between bone resorption biomarkers, 25-hydroxyvitamin D, and interventions. CONCLUSIONS: Moderate consumption (<1 cup/d) of blueberries may be an effective strategy to attenuate bone loss in healthy postmenopausal women. This trial was registered at clinicaltrials.gov as NCT02630797.


Subject(s)
Blueberry Plants , Bone Resorption , Osteoporosis, Postmenopausal , Female , Humans , Rats , Animals , Calcium/urine , Powders , Postmenopause , Cross-Over Studies , Bone Resorption/prevention & control , Biomarkers , Osteoporosis, Postmenopausal/prevention & control
2.
Nutrients ; 13(12)2021 Dec 09.
Article in English | MEDLINE | ID: mdl-34959951

ABSTRACT

Potassium supplementation has been associated with reduced urinary calcium (Ca) excretion and increased Ca balance. Dietary interventions assessing the impact of potassium on bone are lacking. In this secondary analysis of a study designed primarily to determine blood pressure effects, we assessed the effects of potassium intake from potato sources and a potassium supplement on urinary Ca, urine pH, and Ca balance. Thirty men (n = 15) and women (n = 15) with a mean ± SD age and BMI of 48.2 ± 15 years and 31.4 ± 6.1 kg/m2, respectively, were enrolled in a cross-over, randomized control feeding trial. Participants were assigned to a random order of four 16-day dietary potassium interventions including a basal diet (control) of 2300 mg/day (~60 mmol/day) of potassium, and three phases of an additional 1000 mg/day (3300 mg/day(~85 mmol/day) total) of potassium in the form of potatoes (baked, boiled, or pan-heated), French fries (FF), or a potassium (K)-gluconate supplement. Calcium intake for all diets was approximately 700-800 mg/day. Using a mixed model ANOVA there was a significantly lower urinary Ca excretion in the K-gluconate phase (96 ± 10 mg/day) compared to the control (115 ± 10 mg/day; p = 0.027) and potato (114 ± 10 mg/day; p = 0.033). In addition, there was a significant difference in urinary pH between the supplement and control phases (6.54 ± 0.16 vs. 6.08 ± 0.18; p = 0.0036). There were no significant differences in Ca retention. An increased potassium intake via K-gluconate supplementation may favorably influence urinary Ca excretion and urine pH. This trial was registered at ClinicalTrials.gov as NCT02697708.


Subject(s)
Calcium/metabolism , Calcium/urine , Dietary Supplements , Gluconates/administration & dosage , Hypertension/metabolism , Potassium, Dietary/administration & dosage , Solanum tuberosum , Adult , Aged , Aged, 80 and over , Calcium, Dietary/administration & dosage , Cross-Over Studies , Female , Humans , Hydrogen-Ion Concentration , Hypertension/urine , Male , Middle Aged , Young Adult
3.
Nutrients ; 13(5)2021 May 11.
Article in English | MEDLINE | ID: mdl-34064968

ABSTRACT

Increased potassium intake has been linked to improvements in cardiovascular and other health outcomes. We assessed increasing potassium intake through food or supplements as part of a controlled diet on blood pressure (BP), microcirculation (endothelial function), and potassium and sodium retention in thirty pre-hypertensive-to-hypertensive men and women. Participants were randomly assigned to a sequence of four 17 day dietary potassium treatments: a basal diet (control) of 60 mmol/d and three phases of 85 mmol/d added as potatoes, French fries, or a potassium gluconate supplement. Blood pressure was measured by manual auscultation, cutaneous microvascular and endothelial function by thermal hyperemia, utilizing laser Doppler flowmetry, and mineral retention by metabolic balance. There were no significant differences among treatments for end-of-treatment BP, change in BP over time, or endothelial function using a mixed-model ANOVA. However, there was a greater change in systolic blood pressure (SBP) over time by feeding baked/boiled potatoes compared with control (-6.0 mmHg vs. -2.6 mmHg; p = 0.011) using contrast analysis. Potassium retention was highest with supplements. Individuals with a higher cardiometabolic risk may benefit by increasing potassium intake. This trial was registered at ClinicalTrials.gov as NCT02697708.


Subject(s)
Blood Pressure/drug effects , Gluconates , Hypertension/drug therapy , Microcirculation , Potassium, Dietary/administration & dosage , Potassium , Solanum tuberosum/chemistry , Adult , Cardiometabolic Risk Factors , Cross-Over Studies , Diet , Dietary Supplements , Feces/chemistry , Female , Humans , Male , Middle Aged , Potassium/blood , Sodium , Sodium Chloride, Dietary , Sodium, Dietary/administration & dosage , Water-Electrolyte Imbalance , Young Adult
4.
Mol Nutr Food Res ; 63(7): e1801012, 2019 04.
Article in English | MEDLINE | ID: mdl-30659764

ABSTRACT

SCOPE: Resistant starch (RS) is utilized by Gram-negative Bacteroidetes through a starch utilization system (Sus), which requires physical attachment of the bacteria to the substrate. Gram-positive Firmicutes, which include butyrate producers, utilize RS by other mechanisms, such as amylosomes and secreted amylases/glucoamylases. It has been previously shown that fabricated RS [alginate-based starch-entrapped microspheres (SM)] increases butyrate in in vitro human fecal fermentation and was slow fermenting. It has been hypothesized that in vivo SM would disfavor Bacteroidetes and promote Firmicutes, leading to an increase in butyrate production. METHODS AND RESULTS: A C57BL/6J mouse model is used to test type 2 RS (RS2, raw potato) and SM for SCFAs and fecal microbial community structure. Feeding SM for 2 weeks results in 2.4 times higher mol% butyrate in the mouse distal gut than RS2. SM reduces relative abundance of Bacteroidetes and increases Firmicutes in fecal samples at the end of the 2-week feeding. This phylum-level taxonomic shift is not observed in animals fed RS2. CONCLUSION: Through an approach to understand bacterial requirements related to starch utilization, a designed fiber type favors butyrogenic Firmicutes bacteria and provides higher mol% butyrate in the distal gut with potential benefit as an anti-inflammatory agent and to improve gut barrier function.


Subject(s)
Butyrates/metabolism , Colon/metabolism , Firmicutes/physiology , Gastrointestinal Microbiome/physiology , Starch/pharmacokinetics , Animals , Fatty Acids/analysis , Fatty Acids/metabolism , Fatty Acids, Volatile/metabolism , Feces/microbiology , Gastrointestinal Microbiome/genetics , Male , Mice, Inbred C57BL , Solanum tuberosum , Starch/chemistry
5.
J Bone Miner Res ; 33(11): 1940-1947, 2018 11.
Article in English | MEDLINE | ID: mdl-30001469

ABSTRACT

Increases in 25-hydroxyvitamin D concentrations are shown to improve strength in adults; however, data in pediatric populations are scant and equivocal. In this ancillary study of a larger-scale, multi-sited, double-blind, randomized, placebo-controlled vitamin D intervention in US children and adolescents, we examined the associations between changes in vitamin D metabolites and changes in muscle mass, strength, and composition after 12 weeks of vitamin D3 supplementation. Healthy male and female, black and white children and adolescents between the ages of 9 and 13 years from two US states (Georgia 34°N and Indiana 40°N) were enrolled in the study and randomly assigned to receive an oral vitamin D3 dose of 0, 400, 1000, 2000, or 4000 IU/d for 12 weeks between the winter months of 2009 to 2011 (N = 324). Analyses of covariance, partial correlations, and regression analyses of baseline and 12-week changes (post-baseline) in vitamin D metabolites (serum 25(OH)D, 1,25(OH)2 D, intact parathyroid hormone [iPTH]), and outcomes of muscle mass, strength, and composition (total body fat-free soft tissue [FFST], handgrip strength, forearm and calf muscle cross-sectional area [MCSA], muscle density, and intermuscular adipose tissue [IMAT]) were assessed. Serum 25(OH)D and 1,25(OH)2 D, but not iPTH, increased over time, as did fat mass, FFST, forearm and calf MCSA, forearm IMAT, and handgrip strength (p < 0.05). Vitamin D metabolites were not associated with muscle strength at baseline nor after the 12-week intervention. Changes in serum 25(OH)D correlated with decreases in forearm IMAT, whereas changes in serum iPTH predicted increases in forearm and calf MCSA and IMAT (p < 0.05). Overall, increases in 25(OH)D did not influence muscle mass or strength in vitamin D-sufficient children and adolescents; however, the role of iPTH on muscle composition in this population is unknown and warrants further investigation. © 2018 American Society for Bone and Mineral Research.


Subject(s)
Muscles/physiology , Parathyroid Hormone/blood , Vitamin D/analogs & derivatives , Adolescent , Body Composition , Body Weight , Child , Female , Humans , Linear Models , Male , Metabolome , Vitamin D/blood
6.
Clin J Am Soc Nephrol ; 13(7): 1002-1012, 2018 07 06.
Article in English | MEDLINE | ID: mdl-29921736

ABSTRACT

BACKGROUND AND OBJECTIVES: Twenty-four-hour urine phosphorus is commonly used as a surrogate measure for phosphorus intake and absorption in research studies, but its reliability and accuracy are unproven in health or CKD. This secondary analysis sought to determine the reliability and accuracy of 24-hour urine phosphorus as a biomarker of phosphorus intake and absorption in moderate CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Eight patients with stage 3-4 CKD participated in 2-week balance studies with tightly controlled phosphorus and calcium intakes. Thirteen 24-hour urine collections per patient were analyzed for variability and reliability of 24-hour urine phosphorus and phosphorus-to-creatinine ratio. The accuracy of 24-hour urine phosphorus to predict phosphorus intake was determined using a published equation. The relationships of 24-hour urine phosphorus with phosphorus intake, net absorption, and retention were determined. RESULTS: There was wide day-to-day variation in 24-hour urine phosphorus within and among subjects (coefficient of variation of 30% and 37%, respectively). Two 24-hour urine measures were needed to achieve ≥75% reliability. Estimating dietary phosphorus intake from a single 24-hour urine resulted in underestimation up to 98% in some patients and overestimation up to 79% in others. Twenty-four-hour urine phosphorus negatively correlated with whole-body retention but was not related to net absorption. CONCLUSIONS: From a sample of eight patients with moderate CKD on a tightly controlled dietary intake, 24-hour urine phosphorus was highly variable and did not relate to dietary phosphorus intake or absorption, rather it inversely related to phosphorus retention.


Subject(s)
Phosphorus, Dietary/administration & dosage , Phosphorus, Dietary/metabolism , Phosphorus/urine , Renal Insufficiency, Chronic/metabolism , Biomarkers/urine , Diet Therapy , Female , Humans , Male , Middle Aged , Monitoring, Physiologic , Renal Insufficiency, Chronic/therapy , Renal Insufficiency, Chronic/urine
7.
JBMR Plus ; 2(2): 103-108, 2018 03.
Article in English | MEDLINE | ID: mdl-29577111

ABSTRACT

There are limited data on phosphorus balance and the effect of dietary calcium supplements on phosphorus balance in adolescents. The purpose of this study was to determine phosphorus balance and the effect of increasing dietary calcium intake with a supplement on net phosphorus absorption and balance in healthy adolescent girls. This study utilized stored urine, fecal, and diet samples from a previously conducted study that focused on calcium balance. Eleven healthy girls ages 11 to 14 years participated in a randomized crossover study, which consisted of two 3-week periods of a controlled diet with low (817 ± 19.5 mg/d) or high (1418 ± 11.1 mg/d) calcium, separated by a 1-week washout period. Phosphorus intake was controlled at the same level during both placebo and calcium supplementation (1435 ± 23.5 and 1453 ± 28.0 mg/d, respectively, p = 0.611). Mean phosphorus balance was positive by about 200 mg/d and was unaffected by the calcium supplement (p = 0.826). Urinary phosphorus excretion was lower with the calcium supplement (535 ± 42 versus 649 ± 41 mg/d, p = 0.013), but fecal phosphorus and net phosphorus absorption were not significantly different between placebo and calcium supplement (553 ± 60 versus 678 ± 63 versus mg/d, p = 0.143; 876 ± 62 versus 774 ± 64 mg/d, p = 0.231, respectively). Dietary phosphorus underestimates using a nutrient database compared with the content measured chemically from meal composites by ~40%. These results show that phosphorus balance is positive in girls during adolescent growth and that a calcium dietary supplement to near the current recommended level does not affect phosphorus balance when phosphorus intake is at 1400 mg/d, a typical US intake level.

8.
Nutr Metab (Lond) ; 14: 25, 2017.
Article in English | MEDLINE | ID: mdl-28286536

ABSTRACT

BACKGROUND: This study aimed to investigate the relationships among osteocalcin, leptin and metabolic health outcomes in children ages 9-13 years. METHODS: This was a cross-sectional analysis of baseline data from 161 boys and 157 girls (ages 9-13 years) who previously participated in a double-blinded randomized placebo controlled trial of vitamin D supplementation. Relationships among fasting serum total osteocalcin (tOC), undercarboxylated osteocalcin (ucOC), leptin, and metabolic health outcomes were analyzed. RESULTS: Approximately 52% of study participants were obese based on percent body fat cutoffs (>25% for boys and >32% for girls) and about 5% had fasting serum glucose within the prediabetic range (i.e. 100 to 125 mg/dL). Serum tOC was not correlated with leptin, glucose, insulin, HOMA-IR, or HOMA-ß after adjusting for percent body fat. However, serum ucOC negatively correlated with leptin (partial r = -0.16; p = 0.04) and glucose (partial r = -0.16; p = 0.04) after adjustment for percent body fat. Leptin was a positive predictor of insulin, glucose, HOMA-IR, and HOMA-ß after adjusting for age, sex and percent body fat (all p < 0.001). CONCLUSIONS: These data depict an inverse relationship between leptin and various metabolic health outcomes in children. However, the notion that tOC or ucOC link fat with energy metabolism in healthy children was not supported. CLINICAL TRIAL REGISTRATION NUMBER: NCT00931580.

9.
Am J Clin Nutr ; 104(2): 346-53, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27413123

ABSTRACT

BACKGROUND: The bioavailability of potassium should be considered in setting requirements, but to our knowledge, the bioavailability from individual foods has not been determined. Potatoes provide 19-20% of potassium in the American diet. OBJECTIVE: We compared the bioavailability and dose response of potassium from nonfried white potatoes with skin [targeted at 20, 40, and 60 milliequivalents (mEq) K] and French fries (40 mEq K) with potassium gluconate at the same doses when added to a basal diet that contained ∼60 mEq K. DESIGN: Thirty-five healthy, normotensive men and women with a mean ± SD age of 29.7 ± 11.2 y and body mass index (in kg/m(2)) of 24.3 ± 4.4 were enrolled in a single-blind, crossover, randomized controlled trial. Participants were partially randomly assigned to the order of testing for nine 5-d interventions of additional potassium as follows: 0 (control; repeated at phases 1 and 5), 20, 40, and 60 mEq K/d consumed as a potassium gluconate supplement or as unfried potato or 40 mEq K from French fries completed at phase 9. The bioavailability of potassium was determined from the area under the curve (AUC) of serial blood draws and cumulative urinary excretion during a 24-h period and from a kinetic analysis. The effects of the potassium source and dose on the change in blood pressure and augmentation index (AIx) were determined. RESULTS: The serum potassium AUC increased with the dose (P < 0.0001) and did not differ because of the source (P = 0.53). Cumulative 24-h urinary potassium also increased with the dose (P < 0.0001) and was greater with the potato than with the supplement (P < 0.0001). The kinetic analysis showed the absorption efficiency was high across all interventions (>94% ± 12%). There were no significant differences in the change in blood pressure or AIx with the treatment source or dose. CONCLUSIONS: The bioavailability of potassium is as high from potatoes as from potassium gluconate supplements. Future studies that measure the effect of dietary potassium on blood pressure will need to evaluate the effect of various dietary sources on potassium retention and in both normal and hypertensive populations. This trial was registered at clinicaltrials.gov as NCT01881295.


Subject(s)
Diet , Dietary Supplements , Gluconates/pharmacokinetics , Intestinal Absorption , Potassium, Dietary/pharmacokinetics , Potassium/pharmacokinetics , Solanum tuberosum/chemistry , Adolescent , Adult , Area Under Curve , Biological Availability , Cross-Over Studies , Dose-Response Relationship, Drug , Female , Humans , Male , Plant Tubers/chemistry , Potassium/blood , Potassium/urine , Potassium, Dietary/blood , Potassium, Dietary/urine , Single-Blind Method , Vegetables/chemistry , Young Adult
10.
Am J Clin Nutr ; 104(3): 837-43, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27465372

ABSTRACT

BACKGROUND: Dietary soluble corn fiber (SCF) significantly improves calcium absorption in adolescents and the bone strength and architecture in rodent models. OBJECTIVE: In this study, we aimed to determine the skeletal benefits of SCF in postmenopausal women. DESIGN: We used our novel technology of determining bone calcium retention by following the urinary appearance of (41)Ca, a rare long-lived radioisotope, from prelabeled bone to rapidly and sensitively evaluate the effectiveness of SCF in reducing bone loss. A randomized-order, crossover, double-blinded trial was performed in 14 healthy postmenopausal women to compare doses of 0, 10, and 20 g fiber from SCF/d for 50 d. RESULTS: A dose-response effect was shown with 10 and 20 g fiber from SCF/d, whereby bone calcium retention was improved by 4.8% (P < 0.05) and 7% (P < 0.04), respectively. The bone turnover biomarkers N-terminal telopeptide and osteocalcin were not changed by the interventions; however, a significant increase in bone-specific alkaline phosphatase, which is a bone-formation marker, was detected between 0 and 20 g fiber from SCF/d (8%; P = 0.035). CONCLUSION: Daily SCF consumption significantly increased bone calcium retention in postmenopausal women, which improved the bone calcium balance by an estimated 50 mg/d. This study was registered at clinicaltrials.gov as NCT02416947.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Remodeling , Dietary Fiber/therapeutic use , Food, Fortified , Osteoporosis, Postmenopausal/prevention & control , Zea mays/chemistry , Absorptiometry, Photon , Adult , Aged , Biomarkers/blood , Biomarkers/urine , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Calcium Radioisotopes , Cohort Studies , Cross-Over Studies , Dietary Fiber/administration & dosage , Dietary Fiber/adverse effects , Double-Blind Method , Female , Food, Fortified/adverse effects , Humans , Indiana , Middle Aged , Osteoporosis, Postmenopausal/diagnostic imaging , Osteoporosis, Postmenopausal/metabolism , Osteoporosis, Postmenopausal/urine , Prebiotics/administration & dosage , Prebiotics/adverse effects , Solubility , Whole Body Imaging
11.
J Clin Endocrinol Metab ; 101(4): 1710-8, 2016 04.
Article in English | MEDLINE | ID: mdl-26885880

ABSTRACT

CONTEXT: Vitamin D supplementation trials with diabetes-related outcomes have been conducted almost exclusively in adults and provide equivocal findings. OBJECTIVE: The objective of this study was to determine the dose-response of vitamin D supplementation on fasting glucose, insulin, and a surrogate measure of insulin resistance in white and black children aged 9­13 years, who participated in the Georgia, Purdue, and Indiana University (or GAPI) trial: a 12-week multisite, randomized, triple-masked, dose-response, placebo-controlled vitamin D trial. DESIGN: Black and white children in the early stages of puberty (N = 323, 50% male, 51% black) were equally randomized to receive vitamin D3 (0, 400, 1000, 2000, or 4000 IU/day) for 12 weeks. Fasting serum 25-hydroxyvitamin D (25(OH)D), glucose and insulin were assessed at baseline and weeks 6 and 12. Homeostasis model assessment of insulin resistance was used as a surrogate measure of insulin resistance. Statistical analyses were conducted as intent-to-treat using a mixed effects model. RESULTS: Baseline serum 25(OH)D was inversely associated with insulin (r = −0.140, P = 0.017) and homeostasis model assessment of insulin resistance (r = −0.146, P = 0.012) after adjusting for race, sex, age, pubertal maturation, fat mass, and body mass index. Glucose, insulin, and insulin resistance increased (F > 5.79, P < .003) over the 12 weeks, despite vitamin D dose-dependent increases in serum 25(OH)D. CONCLUSIONS: Despite significant baseline inverse relationships between serum 25(OH)D and measures of insulin resistance, vitamin D supplementation had no impact on fasting glucose, insulin, or a surrogate measure of insulin resistance over 12 weeks in apparently healthy children.


Subject(s)
Blood Glucose , Cholecalciferol/administration & dosage , Dietary Supplements , Insulin Resistance/physiology , Insulin/blood , Vitamin D/analogs & derivatives , Adolescent , Black People , Body Composition/physiology , Child , Dose-Response Relationship, Drug , Fasting/blood , Female , Humans , Male , Vitamin D/blood , White People
12.
J Clin Endocrinol Metab ; 101(3): 923-7, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26751193

ABSTRACT

CONTEXT: Citrus fruits contain unique flavanones. One of the most abundant of the flavanones, hesperidin, has been shown to prevent bone loss in ovariectomized rats. OBJECTIVE: The objective of the study was to measure the effect of hesperidin with or without calcium supplementation on bone calcium retention in postmenopausal women. DESIGN: The study was a double-blind, placebo-controlled, randomized-order crossover design of 500 g hesperidin with or without 500 mg calcium supplement in 12 healthy postmenopausal women. Bone calcium retention was determined from urinary excretion of the rare isotope, (41)Ca, from bone. RESULTS: Calcium plus hesperidin, but not hesperidin alone, improved bone calcium retention by 5.5% (P < .04). CONCLUSION: Calcium supplementation (Calcilock), in combination with hesperidin, is effective at preserving bone in postmenopausal women.


Subject(s)
Bone and Bones/drug effects , Bone and Bones/metabolism , Calcium, Dietary/administration & dosage , Calcium/metabolism , Hesperidin/administration & dosage , Postmenopause , Aged , Calcium Radioisotopes/urine , Cross-Over Studies , Dietary Supplements , Double-Blind Method , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/prevention & control , Placebos
13.
J Am Heart Assoc ; 4(8): e001620, 2015 Aug 13.
Article in English | MEDLINE | ID: mdl-26272654

ABSTRACT

BACKGROUND: Calcium is a shortfall essential nutrient that has been a mainstay of osteoporosis management. Recent and limited findings have prompted concern about the contribution of calcium supplementation to cardiovascular risk. A proposed mechanism is through the acceleration of coronary artery calcification. Determining causality between calcium intake and coronary artery calcification has been hindered by a lack of sensitive methodology to monitor early vascular calcium accumulation. The primary study aim was to assess the impact of high calcium intake on coronary artery calcification using innovative calcium tracer kinetic modeling in Ossabaw swine with diet-induced metabolic syndrome. Secondary end points (in vitro wire myography, histopathology, intravascular ultrasound) assessed coronary disease. METHODS AND RESULTS: Pigs (n=24; aged ≈15 months) were fed an atherogenic diet with adequate calcium (0.33% by weight) or high calcium (1.90% from calcium carbonate or dairy) for 6 months. Following 5 months of feeding, all pigs were dosed intravenously with (41)Ca, a rare isotope that can be measured in serum and tissues at a sensitivity of 10(-18) mol/L by accelerator mass spectrometry. Kinetic modeling evaluated early coronary artery calcification using (41)Ca values measured in serial blood samples (collected over 27 days) and coronary artery samples obtained at sacrifice. Serum disappearance of (41)Ca and total coronary artery (41)Ca accumulation did not differ among groups. Secondary end points demonstrated no treatment differences in coronary artery disease or function. CONCLUSION: There was no detectable effect of high calcium diets (from dairy or calcium carbonate) on coronary artery calcium deposition in metabolic syndrome swine.


Subject(s)
Calcium Carbonate/pharmacokinetics , Calcium, Dietary/pharmacokinetics , Coronary Artery Disease/metabolism , Coronary Vessels/metabolism , Dairy Products , Dietary Supplements , Metabolic Syndrome/metabolism , Vascular Calcification/metabolism , Animals , Calcium Carbonate/administration & dosage , Calcium Carbonate/toxicity , Calcium, Dietary/administration & dosage , Calcium, Dietary/toxicity , Cardiac-Gated Imaging Techniques , Coronary Angiography/methods , Coronary Artery Disease/diagnosis , Coronary Artery Disease/etiology , Coronary Artery Disease/physiopathology , Coronary Vessels/diagnostic imaging , Coronary Vessels/physiopathology , Dairy Products/toxicity , Dietary Supplements/adverse effects , Disease Models, Animal , Female , Metabolic Syndrome/diagnosis , Metabolic Syndrome/etiology , Models, Biological , Myography , Risk Assessment , Swine , Swine, Miniature , Tomography, X-Ray Computed , Ultrasonography, Interventional , Vascular Calcification/diagnosis , Vascular Calcification/etiology , Vascular Calcification/physiopathology , Vasoconstriction , Vasodilation
14.
Am J Clin Nutr ; 102(3): 695-703, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26245807

ABSTRACT

BACKGROUND: Postmenopausal estrogen depletion is a major contributing factor to bone loss. Soy isoflavones have variable effects on the prevention of postmenopausal bone loss, which is possibly related to the specific isoflavone content or the variable equol-producing capacity of individuals. OBJECTIVE: We aimed to determine the effects of the content of isoflavones in a soy supplement and the equol-producing ability of the individual on postmenopausal bone calcium retention. DESIGN: The study was a blinded, randomized, crossover intervention trial in 24 postmenopausal women who were prescreened for their ability to convert daidzein to equol. Women were equilibrated with (41)Ca before the intervention. Interventions were 5 soy isoflavone oral supplements (2 doses of a genistein-rich soy supplement and 3 doses of mixed isoflavones in various proportions) and a bisphosphonate (risedronate). Each intervention was given sequentially for 50 d followed by a 50-d washout period. The percentage of bone calcium retention was determined from the change in urinary (41)Ca:calcium. RESULTS: Interventions that ranged from 52 to 220 mg total isoflavones/d increased bone calcium retention between 3.4% and 7.6% (P < 0.05), which was a moderate effect compared with that of risedronate at 15.3% (95% CI: 7.1%, 22.7%; P = 0.0014). The most-effective soy intervention delivered 105.23 mg total isoflavones/d as genistein, daidzein, and glycitein in their natural ratios and increased bone calcium retention by 7.6% (95% CI: 4.9%, 10.2%; P < 0.0001). Genistein, at 52.85 mg/d, increased bone calcium retention by 3.4% (95% CI: 0.5%, 6.2%; P = 0.029); but there was no benefit at higher amounts (113.52 mg/d). There was no difference (P = 0.5) in bone calcium retention between equol producers and nonproducers. CONCLUSION: Soy isoflavones, although not as potent as risedronate, are effective bone-preserving agents in postmenopausal women regardless of their equol-producing status, and mixed isoflavones in their natural ratios are more effective than enriched genistein. This trial was registered at clinicaltrials.gov as NCT00244907.


Subject(s)
Bone and Bones/drug effects , Calcium/metabolism , Equol/administration & dosage , Glycine max/chemistry , Postmenopause , Administration, Oral , Aged , Cross-Over Studies , Dietary Supplements , Dose-Response Relationship, Drug , Female , Genistein/administration & dosage , Humans , Isoflavones/administration & dosage , Middle Aged , Osteoporosis, Postmenopausal/prevention & control , Phytoestrogens/administration & dosage , Risedronic Acid/pharmacology
15.
J Agric Food Chem ; 62(26): 6108-17, 2014 Jul 02.
Article in English | MEDLINE | ID: mdl-24894797

ABSTRACT

Plant-derived polyphenols have been shown to influence bone turnover and bone properties in the estrogen-depleted state. We used a crossover design in ovariectomized rats (n = 16 rats for each diet) to investigate the effect of supplementation of two doses each of blueberry, plum, grape, grape seed extract, and resveratrol on bone. We tested the aglycon and glucoside forms of genistein to quantify differences in efficacy on bone calcium retention. Rats were given an intravenous dose of 45Ca to prelabel bone, and bone calcium retention was assessed by urinary excretion of 45Ca:Ca ratio during an intervention period compared with nonintervention. Genistein aglycon increased bone calcium retention significantly (p<0.05) more than the glucoside (22% vs 13%, respectively). Plum extract (0.45% w/w total dietary polyphenols) and resveratrol (0.2% w/w total dietary polyphenols) were also effective, increasing bone calcium retention by 20% (p=0.0153) and 14% (p=0.0012), respectively. Several polyphenolic-rich diets improved bone calcium retention.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Dietary Supplements , Fruit/chemistry , Glycine max/chemistry , Osteoporosis, Postmenopausal/diet therapy , Plant Extracts/therapeutic use , Prunus/chemistry , Animals , Bone Density Conservation Agents/chemistry , Female , Genistein/chemistry , Genistein/therapeutic use , Glucosides/chemistry , Glucosides/therapeutic use , Humans , Hydrolysis , Plant Extracts/chemistry , Random Allocation , Rats, Sprague-Dawley , Seeds/chemistry
16.
Br J Nutr ; 110(7): 1292-303, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23507173

ABSTRACT

Adolescence is a time for rapid growth that represents an opportunity to influence peak bone mass. Prebiotic agents, such as galacto-oligosaccharides (GOS), increase Ca absorption in animal models and postmenopausal women. The objectives of the present study were to investigate the dose-response relationship of GOS supplementation on Ca absorption during growth and to assess changes in colonic microbiota to better understand the mechanism by which GOS is acting. A total of thirty-one healthy adolescent girls aged 10-13 years consumed smoothie drinks twice daily with 0, 2·5 or 5 g GOS for three 3-week periods in a random order. Fractional Ca absorption was determined from urinary Ca excretion over 48 h at the end of each 3-week period using a dual stable isotope method. Faecal microbiota and bifidobacteria were assessed by PCR-denaturing gradient gel electrophoresis and quantitative PCR. Fractional Ca absorption after the 48 h treatment with control, 5 and 10 g GOS/d was 0·393 (SD 0·092), 0·444 (SD 0·086) and 0·419 (SD 0·099), respectively. Significant improvements in Ca absorption were seen with both low and high doses of GOS compared with the control (P,0·02), but itwas not a dose-response relationship. The increase in absorption was greatest in the urine collected after 24 h, which is consistent with lower gut absorption. Faecal bifidobacteria increased (control 10·89 (SD 13·86), 5 g GOS 22·80 (SD 15·74) and 10 g GOS 11·54 (SD 14·20)) with the GOS treatment (P,0·03). The results suggest that daily consumption of 5 g GOS increases Ca absorption, which may be mediated by the gut microbiota, specifically bifidobacteria.


Subject(s)
Bifidobacterium , Calcium, Dietary/metabolism , Calcium/metabolism , Feces/microbiology , Galactose/pharmacology , Intestines/microbiology , Oligosaccharides/pharmacology , Adolescent , Calcium/urine , Calcium, Dietary/urine , Child , Double-Blind Method , Female , Humans , Intestinal Absorption
17.
Kidney Int ; 83(5): 959-66, 2013 May.
Article in English | MEDLINE | ID: mdl-23254903

ABSTRACT

Patients with chronic kidney disease (CKD) are given calcium carbonate to bind dietary phosphorus, reduce phosphorus retention, and prevent negative calcium balance; however, data are limited on calcium and phosphorus balance during CKD to support this. Here, we studied eight patients with stage 3 or 4 CKD (mean estimated glomerular filtration rate 36 ml/min) who received a controlled diet with or without a calcium carbonate supplement (1500 mg/day calcium) during two 3-week balance periods in a randomized placebo-controlled cross-over design. All feces and urine were collected during weeks 2 and 3 of each balance period and fasting blood, and urine was collected at baseline and at the end of each week. Calcium kinetics were determined using oral and intravenous (45)calcium. Patients were found to be in neutral calcium and phosphorus balance while on the placebo. Calcium carbonate supplementation produced positive calcium balance, did not affect phosphorus balance, and produced only a modest reduction in urine phosphorus excretion compared with placebo. Calcium kinetics demonstrated positive net bone balance but less than overall calcium balance, suggesting soft-tissue deposition. Fasting blood and urine biochemistries of calcium and phosphate homeostasis were unaffected by calcium carbonate. Thus, the positive calcium balance produced by calcium carbonate treatment within 3 weeks cautions against its use as a phosphate binder in patients with stage 3 or 4 CKD, if these findings can be extrapolated to long-term therapy.


Subject(s)
Calcium Carbonate/administration & dosage , Calcium/blood , Chelating Agents/administration & dosage , Kidney/drug effects , Phosphorus/blood , Renal Insufficiency, Chronic/drug therapy , Administration, Oral , Aged , Analysis of Variance , Biomarkers/blood , Biomarkers/urine , Calcium/urine , Calcium Carbonate/adverse effects , Chelating Agents/adverse effects , Cross-Over Studies , Feces/chemistry , Female , Glomerular Filtration Rate , Humans , Indiana , Kidney/metabolism , Kidney/physiopathology , Kinetics , Least-Squares Analysis , Male , Middle Aged , Phosphorus/urine , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/physiopathology , Renal Insufficiency, Chronic/urine , Severity of Illness Index , Treatment Outcome
18.
Bone ; 51(4): 795-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22750015

ABSTRACT

Low serum 25-hydroxyvitamin D [25 (OH) D] is common in healthy children particularly in blacks. However, serum 25 (OH) D concentrations for optimal bone turnover in children is unknown and few data exist that describe effects of increasing serum 25 (OH) D on bone turnover markers during puberty. The purpose of this study was to determine the relationships between serum 25 (OH) D and changes in serum 25 (OH) D and bone turnover in white and black pubertal adolescents. Bone turnover markers were measured in 318 healthy boys and girls from Georgia (34°N) and Indiana (40°N) who participated in a study of oral vitamin D(3) supplementation (0 to 4000 IU/d). Serum 25 (OH) D, osteocalcin, bone alkaline phosphatase, and urine N-telopeptide cross-links were measured at baseline and 12 weeks. Relationships among baseline 25 (OH) D and bone biomarkers, and between changes over 12 weeks were determined and tested for effects of race, sex, latitude, and baseline 25 (OH) D. Median 25 (OH) D was 27.6 ng/mL (n=318, range 10.1-46.0 ng/mL) at baseline and 34.5 ng/mL (n=302, range 9.7-95.1 ng/mL) at 12 weeks. Neither baseline nor change in 25 (OH) D over 12 weeks was associated with bone turnover. The lack of association was not affected by race, sex, latitude, or baseline serum 25 (OH) D. Serum 25 (OH) D in the range of 10-46 ng/mL appears to be sufficient for normal bone turnover in healthy black and white pubertal adolescents.


Subject(s)
Black People , Bone Remodeling , Puberty , Vitamin D/analogs & derivatives , White People , Adolescent , Female , Humans , Male , Vitamin D/blood
19.
J Food Sci ; 77(4): H88-94, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22394255

ABSTRACT

UNLABELLED: Age-related changes in calcium metabolism play a role in the development of osteoporosis. A 4-wk feeding study was conducted in 5-mo-old ovariectomized (OVX) Sprague-Dawley rats to assess the effect of various dietary fibers on mineral metabolism and bone health parameters. There were 6 treatment groups: sham-Control, OVX-Control, OVX rats receiving daily estradiol (E2) injections, and OVX rats receiving an AIN-93M diet supplement with either an inulin-based fiber (Synergy1® or Fruitafit HD®) or a novel fiber (polydextrose) at 5% wt. of diet. Calcium and magnesium metabolic balances were performed after early (3 d) and late exposure (4 wk) to dietary treatments. Rats receiving polydextrose had significantly higher net calcium absorption efficiency and retention than all control groups and a trend (P≤ 0.10) for higher calcium absorption when compared to inulin-based fibers after early exposure but the advantage did not persist over long-term exposure. The inulin-based fibers had positive chronic effects on calcium metabolism that were related to changes in the gut, that is, production of short chain fatty acids and higher cecal wall weights. All fibers improved magnesium absorption and retention in early and late metabolic balances; effects on magnesium metabolism were more pronounced than for calcium. PRACTICAL APPLICATION: Steady growth in US middle-aged and elderly populations has led to higher incidences of several chronic diseases including osteoporosis, a bone disease that primarily affects postmenopausal women. Recent research suggests that certain dietary fibers (prebiotics) enhance mineral absorption and may impart bone health benefits. This work examines the impact of prebiotic supplementation on mineral metabolism and bone health using a postmenopausal rat model. Study findings will aid future investigations in ascertaining the factors related to potential bone health benefits of prebiotic which will aid in developing an effective prebiotics food product/supplement that will address the bone health needs of consumers.


Subject(s)
Calcium/metabolism , Disease Models, Animal , Intestinal Absorption , Inulin/therapeutic use , Magnesium/metabolism , Osteoporosis, Postmenopausal/prevention & control , Prebiotics , Animals , Bone Density , Bone and Bones/metabolism , Cecum/metabolism , Cecum/pathology , Fatty Acids, Volatile/metabolism , Female , Gastrointestinal Contents/chemistry , Glucans/chemistry , Glucans/therapeutic use , Humans , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Inulin/chemistry , Kinetics , Oligosaccharides/chemistry , Oligosaccharides/therapeutic use , Osteoporosis, Postmenopausal/metabolism , Osteoporosis, Postmenopausal/pathology , Rats , Rats, Sprague-Dawley , Solubility
20.
Am J Clin Nutr ; 94(5): 1163-70, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21918216

ABSTRACT

BACKGROUND: Dairy product and calcium consumption have been associated with modifying body fat and body weight in children and adults. OBJECTIVE: In overweight adolescent boys and girls, we aimed to determine the effect of the doubling of habitual calcium intake to the recommended intake from dairy or calcium carbonate on energy balance and purported mechanisms including fecal fat excretion, macronutrient use, and parathyroid hormone suppression. DESIGN: Twenty-five girls with a mean (±SD) BMI (in kg/m(2)) of 33 ± 5 and 17 boys with a BMI of 28 ± 5, aged 12-15 y, participated in two 3-wk controlled feeding sessions that used a crossover design in random order as a summer research camp. In one session, 756 mg Ca/d was consumed; in the other session, an additional 650 mg Ca/d was provided as dairy or calcium carbonate supplements that were matched to the control in macronutrient content. Total energy and macronutrient intakes were controlled and were the same for the 2 sessions for each subject. Primary outcome measures were energy balance, fecal fat excretion, lipid oxidation, and postprandial energy expenditure. RESULTS: There were no effects of quantity or source of calcium on energy or fat balance, despite calcium-induced increases (P <0.01) in postprandial serum parathyroid hormone suppression. CONCLUSION: These data lend little evidence to support the proposed mechanisms for the relation between an increase in calcium intake from calcium carbonate or dairy and weight loss or weight maintenance in children. This trial was registered at clinicaltrials.gov as NCT00592137.


Subject(s)
Calcium, Dietary/administration & dosage , Dairy Products , Energy Intake/physiology , Energy Metabolism/physiology , Overweight/diet therapy , Overweight/metabolism , Adolescent , Calcium, Dietary/metabolism , Calorimetry, Indirect , Child , Cross-Over Studies , Fats/metabolism , Feces/chemistry , Female , Humans , Male , Overweight/blood , Parathyroid Hormone/blood
SELECTION OF CITATIONS
SEARCH DETAIL